Hepatocyte growth factor activates phosphoinositide 3-kinase C2 beta in renal brush-border plasma membranes.

PubWeight™: 0.80‹?›

🔗 View Article (PMC 1222704)

Published in Biochem J on August 01, 2002

Authors

Vladiana Crljen1, Stefano Volinia, Hrvoje Banfic

Author Affiliations

1: Department of Physiology and Croatian Institute for Brain Research, School of Medicine, University of Zagreb, Salata 3, 10000 Zagreb, Croatia.

Articles cited by this

Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65

A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem (1957) 173.99

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68

Signaling through phosphatidylcholine breakdown. J Biol Chem (1990) 5.36

C2-domains, structure and function of a universal Ca2+-binding domain. J Biol Chem (1998) 5.01

Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res (1999) 4.79

The PX domains of p47phox and p40phox bind to lipid products of PI(3)K. Nat Cell Biol (2001) 4.64

The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem (1999) 4.62

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell (1994) 4.10

Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene (1991) 3.41

Structure and physiological function of calpains. Biochem J (1997) 2.62

PtdIns(3)P regulates the neutrophil oxidase complex by binding to the PX domain of p40(phox). Nat Cell Biol (2001) 2.39

A high yield preparation for rat kidney brush border membranes. Different behaviour of lysosomal markers. Biochim Biophys Acta (1981) 2.33

The polyphosphoinositide cycle exists in the nuclei of Swiss 3T3 cells under the control of a receptor (for IGF-I) in the plasma membrane, and stimulation of the cycle increases nuclear diacylglycerol and apparently induces translocation of protein kinase C to the nucleus. EMBO J (1991) 2.17

Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol (1995) 1.91

Hepatocyte growth factor-induced scatter of Madin-Darby canine kidney cells requires phosphatidylinositol 3-kinase. J Biol Chem (1995) 1.82

Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int (2001) 1.69

Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol (2000) 1.55

Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Cancer Res (1992) 1.40

Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem (1998) 1.38

A simple isolation method for basal-lateral plasma membranes from rat kidney cortex. Membr Biochem (1981) 1.35

The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha. J Biol Chem (1998) 1.34

The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles. J Biol Chem (2000) 1.25

Insulin activates the alpha isoform of class II phosphoinositide 3-kinase. J Biol Chem (1999) 1.23

Recruitment of the class II phosphoinositide 3-kinase C2beta to the epidermal growth factor receptor: role of Grb2. Mol Cell Biol (2001) 1.23

A type II phosphoinositide 3-kinase is stimulated via activated integrin in platelets. A source of phosphatidylinositol 3-phosphate. J Biol Chem (1998) 1.19

Renotropic functions of hepatocyte growth factor in renal regeneration after unilateral nephrectomy. J Biol Chem (1991) 1.15

PX domains: attracted by phosphoinositides. Nat Cell Biol (2001) 1.13

Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. Oncogene (1992) 1.08

Cytoskeleton-dependent endocytosis is required for apical type 1 angiotensin II receptor-mediated phospholipase C activation in cultured rat proximal tubule cells. J Clin Invest (1992) 1.05

Hormonal interactions with the proximal Na(+)-H+ exchanger. Am J Physiol (1990) 0.97

An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C. J Biol Chem (1996) 0.96

Cloning and characterization of a novel class II phosphoinositide 3-kinase containing C2 domain. Biochem Biophys Res Commun (1998) 0.93

Collagen type IV stimulates an increase in intracellular Ca2+ in pancreatic acinar cells via activation of phospholipase C. Biochem J (1994) 0.92

A novel class II phosphoinositide 3-kinase predominantly expressed in the liver and its enhanced expression during liver regeneration. J Biol Chem (1998) 0.92

Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res (1993) 0.88

Presence and activation of nuclear phosphoinositide 3-kinase C2beta during compensatory liver growth. J Biol Chem (2001) 0.87

Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem Biophys Res Commun (1997) 0.85

Growth factors and the kidney: regulation of epithelial cell movement and morphogenesis. Am J Physiol (1996) 0.83

Different endothelin receptor subtypes are involved in phospholipid signalling in the proximal tubule of rat kidney. Pflugers Arch (1996) 0.81

Inositol lipid signalling occurs in brush-border membranes during initiation of compensatory renal growth in the rat. Biochem J (1993) 0.76

Articles by these authors

(truncated to the top 100)

MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02

miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51

Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65

MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97

MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A (2007) 9.82

MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45

Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell (2009) 8.62

The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60

E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell (2008) 7.56

Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04

MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood (2009) 5.87

Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res (2006) 5.72

Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56

Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40

MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 5.40

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23

Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res (2008) 5.16

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79

MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33

Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A (2008) 4.26

miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15

MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A (2006) 3.80

MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77

Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52

MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol (2009) 3.29

A microRNA signature for a BMP2-induced osteoblast lineage commitment program. Proc Natl Acad Sci U S A (2008) 3.29

MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 3.19

Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res (2008) 3.16

The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature (2002) 3.02

p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med (2011) 2.93

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol (2013) 2.86

miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res (2012) 2.52

EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46

MicroRNA expression profiling using microarrays. Nat Protoc (2008) 2.44

MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35

Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology (2009) 2.29

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25

Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A (2010) 2.05

Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A (2011) 1.96

MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst (2010) 1.94

Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci U S A (2010) 1.94

Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence. J Virol (2008) 1.86

A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc (2009) 1.85

Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res (2010) 1.82

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest (2013) 1.72

Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood (2009) 1.70

The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem (2008) 1.67

The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood (2012) 1.60

Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood (2004) 1.59

A role for the WWOX gene in prostate cancer. Cancer Res (2006) 1.45

A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A (2013) 1.44

miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood (2011) 1.44

Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol (2013) 1.34

Retracted Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem (2009) 1.33

Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci U S A (2013) 1.32

Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood (2009) 1.29

Non-coding RNAs: a key to future personalized molecular therapy? Genome Med (2010) 1.29

Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells. Biochem Pharmacol (2010) 1.28

Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res (2006) 1.26

MicroRNA expression profiling of male breast cancer. Breast Cancer Res (2009) 1.22

GAMES identifies and annotates mutations in next-generation sequencing projects. Bioinformatics (2010) 1.21

UCbase & miRfunc: a database of ultraconserved sequences and microRNA function. Nucleic Acids Res (2008) 1.19

Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology (2008) 1.19

MicroRNA expression profiling in human Barrett's carcinogenesis. Int J Cancer (2011) 1.17

MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res (2013) 1.17

Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer (2011) 1.16

TOM: a web-based integrated approach for identification of candidate disease genes. Nucleic Acids Res (2006) 1.15

Comparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues. PLoS One (2013) 1.14

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. J Exp Med (2013) 1.13

Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. Int J Oncol (2009) 1.11

Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood (2005) 1.08

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood (2007) 1.07

B-cell malignancies in microRNA Eμ-miR-17~92 transgenic mice. Proc Natl Acad Sci U S A (2013) 1.06

miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci U S A (2012) 1.05

Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol (2012) 1.03

Selected microRNAs define cell fate determination of murine central memory CD8 T cells. PLoS One (2010) 1.02

Zinc replenishment reverses overexpression of the proinflammatory mediator S100A8 and esophageal preneoplasia in the rat. Gastroenterology (2008) 1.02

Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. Mol Cancer (2013) 1.01

Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation. Proc Natl Acad Sci U S A (2011) 1.00

Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol (2011) 1.00

Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. Diagn Mol Pathol (2010) 0.98

Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer Res (2014) 0.98

Wwox suppresses prostate cancer cell growth through modulation of ErbB2-mediated androgen receptor signaling. Mol Cancer Res (2007) 0.95

Identification of differentially expressed genes in human salivary gland tumors by DNA microarrays. Mol Cancer Ther (2002) 0.95

TOM: enhancement and extension of a tool suite for in silico approaches to multigenic hereditary disorders. Bioinformatics (2007) 0.94

Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer (2009) 0.93

Common fragile site tumor suppressor genes and corresponding mouse models of cancer. J Biomed Biotechnol (2010) 0.93

Analysis of MG63 osteoblastic-cell response to a new nanoporous implant surface by means of a microarray technology. Clin Oral Implants Res (2004) 0.92

MicroRNA expression signatures in solid malignancies. Cancer J (2012) 0.92

Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression. Proc Natl Acad Sci U S A (2013) 0.92

GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGF{beta} effectors, Drosha and microRNAs with opposite oncogenic potentials. Nucleic Acids Res (2010) 0.91

Expression profiles of craniosynostosis-derived fibroblasts. Mol Med (2002) 0.88

Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood (2014) 0.87

OMiR: Identification of associations between OMIM diseases and microRNAs. Genomics (2010) 0.87

Molecular classification of nodal metastasis in primary larynx squamous cell carcinoma. Transl Res (2007) 0.86

SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest (2014) 0.86

Nuclear phosphoinositide 3-kinase C2beta activation during G2/M phase of the cell cycle in HL-60 cells. Biochim Biophys Acta (2003) 0.86

Zirconium oxide: analysis of MG63 osteoblast-like cell response by means of a microarray technology. Biomaterials (2004) 0.85

Next generation analysis of breast cancer genomes for precision medicine. Cancer Lett (2013) 0.85